Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Identification Of Potential Therapeutic Targets By Gene-expression Profiling In Pancreatic Endocrine Tumors.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Identification Of Potential Therapeutic Targets By Gene-expression Profiling In Pancreatic Endocrine Tumors.

    • Related Experiment Videos

    Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors.

    Anne Couvelard1, Jiangting Hu, Graham Steers

    • 1Department of Pathology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Clichy, France. anne.couvelard@bjn.aphp.fr

    Gastroenterology
    |October 27, 2006

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Gene expression profiling of pancreatic endocrine tumors (PETs) identified key differences between nonmetastatic and metastatic forms. These findings may lead to new diagnostic markers for PETs.

    Related Experiment Videos

    Area of Science:

    • Oncology
    • Molecular Biology
    • Genomics

    Background:

    • Histologic criteria alone are insufficient for predicting the biological behavior of pancreatic endocrine tumors (PETs).
    • Understanding gene expression differences is crucial for distinguishing between nonmetastatic and metastatic PETs.

    Purpose of the Study:

    • To characterize the gene expression profile of PETs using complementary DNA (cDNA) microarray.
    • To identify specific gene expression differences between nonmetastatic and metastatic PETs.

    Main Methods:

    • Analysis of 24 well-differentiated PETs (12 benign, 12 metastatic carcinomas) using cDNA microarray.
    • RNA extraction, microarray hybridization, imaging, and statistical analysis were performed.
    • Immunohistochemical validation of microarray data using PET tissue arrays from 129 archival tumors.

    Main Results:

    • 123 transcripts differentiated nonmetastatic from metastatic PETs (72 up-regulated, 51 down-regulated in malignant tumors).
    • Key pathways identified include angiogenesis, tyrosine kinase signaling, calcium-dependent signaling, and drug response.
    • Differential expression of CD34, E-selectin, MKK4, and MDR1 was confirmed in metastatic versus nonmetastatic PETs.

    Conclusions:

    • This study offers insights into the molecular pathways driving tumorigenesis in PETs.
    • Several identified genes show potential as novel molecular markers for PET detection and treatment.